CADL

Candel is a pre-revenue, clinical-stage viral-immunotherapy developer, and the fundamentals confirm it: the only 'revenue' in the data is a stale $125K collaboration figure from FY2022, which makes the headline P/S of 5,760x and the -30,546% net margin meaningless rather than alarming. Management is explicit that it has 'never generated any revenue from product sales' and does 'not expect to do so in the foreseeable future,' with an accumulated deficit of $230.4M. This is not a business you value on multiples — it is a binary bet on one asset clearing the FDA.

The balance sheet is adequate but tightening. Cash of $120M against roughly $38M of annual operating cash burn implies a couple of years of runway, but the company leaned on financing to get there: shares outstanding jumped 55.1% YoY (severe dilution), total liabilities rose 80.7% and liabilities/equity sits at 1.41x after Candel drew $50M under the October 2025 Trinity loan to repay the SVB facility. Stockholders' equity fell 21.7% to $51.9M. R&D climbed 57.9% to $30.5M as Phase 3 work continued, so burn is unlikely to ease, and further raises — dilutive or debt — are probable before any approval.